Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab
Oncologist - United States
doi 10.1634/theoncologist.2018-0611
Full Text
Open PDFAbstract
Available in full text
Date
January 31, 2020
Authors
Publisher
Alphamed Press